PRP vs Exosomes for Hair Loss: How They Differ and What the Evidence Shows

PRP and exosomes are both regenerative approaches to thinning hair, but they are not the same category of thing: PRP is an autologous treatment prepared from your own blood and injected into the scalp, supported by randomized controlled trials and meta-analyses, while exosome preparations are investigational extracellular vesicles that at Arbour Longevity are applied topically to the scalp surface only and are never injected.

The short version. PRP—platelet-rich plasma—starts with a blood draw from your own arm. The blood is spun to concentrate the platelets, and that concentrate is injected into the thinning areas of the scalp. Nothing foreign is introduced, and the evidence base includes multiple randomized trials and several meta-analyses in androgenetic alopecia. Exosomes are nanoscale vesicles that cells release to carry signaling cargo. At Arbour they are applied to the surface of the scalp, usually after microneedling, using Phase 2 research preparations only. They are investigational, they are not a cure for hair loss, and they are not proven to regrow hair. We describe them on exactly those terms.

This is the head-to-head. For either treatment alone, see how PRP hair restoration works and exosome therapy for hair growth.

What Is Actually Causing the Thinning

Both treatments are usually considered for the same problem. Androgenetic alopecia—pattern hair loss—is a chronic, non-scarring disorder characterized by progressive miniaturization of the hair follicle. Follicles do not vanish. They shrink, cycle by cycle, producing finer and shorter hairs until they stop contributing meaningful coverage.

A 2025 review in the European Journal of Dermatology describes the mechanism as multifactorial. Genetic factors are the most important determinant of differences between patients, and an abnormal increase in 5-alpha reductase activity and androgen receptors within hair follicles plays a decisive role. Follicular microinflammation, oxidative stress, loss of hair follicle stem cells and metabolic syndrome are also associated with the condition (Chen et al., Eur J Dermatol, 2025, DOI). Minoxidil and finasteride remain the established medications, and that review notes some patients show little improvement on them—much of why regenerative options get asked about at all.

Two things follow. The target is a living but underperforming follicle, not an absent one, which is why signaling-based approaches are biologically plausible here. And because the process is progressive, no single treatment stops it permanently—which applies to every option on this page.

How PRP Works

Platelets are not just clotting cells. Their granules are packed with growth factors, and concentrating them raises the local dose of those signals where they are placed.

A review in Cells mapping regenerative pathways in hair loss describes several routes: platelet-derived growth factors prolong the anagen (growing) phase via FGF-7, induce cell growth through ERK activation, stimulate follicle development through beta-catenin, and suppress apoptotic signals through Bcl-2 release and Akt activation. It also identifies Wnt signaling in dermal papilla cells as key to stimulating hair growth (Gentile and Garcovich, Cells, 2019, DOI).

The practical appeal is straightforward: the material is autologous—yours—so no donor product is involved. More on our aesthetic PRP page.

What the PRP Trials and Meta-Analyses Report

This is where PRP separates itself. A systematic review and meta-analysis of randomized controlled trials in the Journal of Cutaneous Medicine and Surgery pooled nine trials involving 238 patients with androgenetic alopecia. PRP increased hair density at both three and six months with statistically significant differences compared with placebo; hair count and diameter increased against baseline but not significantly against placebo. Two of seven studies reporting safety noted adverse reactions, and no serious adverse reactions were found (Zhang et al., J Cutan Med Surg, 2023, DOI).

An earlier meta-analysis of six studies in 177 patients found significantly increased hair number per square centimeter after PRP injections versus control (mean difference 17.90, 95% CI 5.84–29.95, P = .004) and increased hair thickness (mean difference 0.22, 95% CI 0.07–0.38, P = .005), while cautioning that it pooled many small studies (Giordano et al., J Cosmet Dermatol, 2017, DOI). A larger analysis of fourteen studies covering 431 patients reported a pooled mean difference of 27.55 hairs per square centimeter (95% CI 14.04–41.06), with hair diameter's confidence interval crossing zero; those authors rated the evidence low quality with high heterogeneity and evident publication bias (Kieling et al., An Bras Dermatol, 2024, DOI).

We include that last assessment deliberately. The honest summary is not that PRP is proven beyond question, but that it has been tested repeatedly against placebo, those trials consistently favor it for hair density, and reviewers who pool them keep flagging small samples and the lack of a standardized preparation protocol.

Against the standard medications, two network meta-analyses put PRP in the same conversation: one found PRP, finasteride 1 mg, minoxidil 5% and 2%, and dutasteride approximately equivalent in mean change in hair count (Gupta et al., J Eur Acad Dermatol Venereol, 2018, DOI), and a second, drawing on 30 randomized trials in men, ranked PRP first among non-surgical monotherapies for male androgenetic alopecia while judging the evidence quality of the top-ranked therapies to be low (Gupta et al., J Dermatolog Treat, 2020, DOI).

For women, a systematic review covering 42 studies and 1,569 cases including 776 female participants reported positive efficacy for PRP in female pattern hair loss by hair density, again calling for standardized protocols (Zhou et al., Front Pharmacol, 2021, DOI).

PRP is also frequently studied alongside minoxidil rather than instead of it. A meta-analysis of six randomized trials with 343 participants found the combination significantly improved hair density (weighted mean difference 9.14, 95% CI 6.57–11.70) and hair diameter (WMD 4.72, 95% CI 3.21–6.23) compared with either alone (Xiao et al., Aesthetic Plast Surg, 2024, DOI). A review of five further randomized trials found hair density better with PRP plus minoxidil than minoxidil alone at one, three and five to six months, with comparable adverse event rates and certainty of evidence rated low to very low (Yao et al., PLoS One, 2024, DOI).

How Exosomes Work, and What Is Currently Known

Exosomes are small extracellular vesicles released by cells, carrying proteins, lipids and nucleic acids as a delivery system for cell-to-cell signaling. The interest in hair is that this cargo overlaps with pathways governing the follicle cycle.

Laboratory work supports the mechanism. A 2024 study treated human dermal papilla cells with adipose stem cell-derived exosomes and observed increased proliferation, upregulation of hair growth-related genes including ALP, VCAN, beta-catenin and LEF-1, and activation of the Wnt/beta-catenin pathway; in follicle organ culture the same preparations promoted hair shaft elongation (Lee et al., Int J Dermatol, 2024, DOI). Several of its authors are affiliated with the company producing the preparation studied, which is worth knowing when weighing it.

Now the part that matters most, which we will not soften. Human evidence for exosomes in hair loss is early, small and largely uncontrolled.

A systematic review identified sixteen studies on exosomes for hair restoration—fifteen preclinical and one clinical. Within it, topical adipose-derived stem cell exosomes were applied in 39 patients with androgenetic alopecia with reported increases in hair density and thickness, and no significant adverse reactions had been reported at that point. The authors concluded that clinical evidence supporting exosome treatment is limited and that further studies are needed to define its mechanism, optimize delivery, and address important safety concerns (Gupta et al., J Cosmet Dermatol, 2023, DOI).

A separate review searching clinical trial databases found no registered trials relevant to hair growth at the time, and stated plainly that data showing efficacy and safety of exosome therapy for alopecia are lacking, with gaps around exosome source, delivery mechanism and dosage (Kost et al., J Cosmet Dermatol, 2022, DOI).

The most recent review of clinical use examined 48 studies and found nine relevant to alopecia, covering 125 patients who received an exosome treatment for hair loss. Side effects there were rare, but the review noted that in dermatology more broadly at least ten serious adverse events have been reported, and called for larger well-designed trials, consistent manufacturing standards and regulatory oversight (Queen and Avram, Dermatol Surg, 2024, DOI).

That is why our sourcing policy is narrow: with these preparations, manufacturing quality is not a detail, it is the main safety variable.

How Each One Is Delivered at Arbour Longevity

PRP is injected into the scalp. We draw your blood, concentrate the platelet fraction, and inject that concentrate into the thinning regions—a same-visit procedure using your own tissue.

Exosomes are applied topically. They are never injected. The scalp is typically prepared with microneedling, and the preparation is applied to the skin surface. We use Phase 2 research preparations only and describe them to every patient as investigational. We do not present them as a cure, and we do not claim they are proven to regrow hair.

The one small prospective study closest to this approach followed 16 men aged 36 to 45 with mild to moderate androgenetic alopecia who had microneedling followed by topical exosome application. At twelve months the reported average increase in hair density was 35 hairs per square centimeter (standard deviation 6.5), and mild side effects including scalp tenderness and slight irritation resolved within 48 hours. It was open-label with no control group, and the authors called for larger samples and longer follow-up (Wan et al., Aesthetic Plast Surg, 2025, DOI). Sixteen uncontrolled patients is a signal worth following, not a basis for promises.

Sessions and Timelines

We set the number of sessions at consultation rather than publishing a fixed course, because the right schedule depends on the pattern and stage of thinning and how your scalp responds. What we can tell you is the timescale the research works on. PRP meta-analyses measured hair density against placebo at three and six months (Zhang et al., 2023, DOI), and the topical exosome study assessed at one, three, six and twelve months (Wan et al., 2025, DOI).

So: months, not weeks. Follicles cycle slowly, and anyone promising a fast answer is not describing hair biology.

Who Each One Suits

PRP tends to be the starting point when the goal is the most evidence-supported regenerative option available, when pattern hair loss is early to moderate with follicles miniaturized rather than long gone, and when using your own tissue matters to you. It is the option with randomized trials behind it in both men and women (Zhang et al., 2023, DOI).

Topical exosomes tend to come up for people who want an investigational adjunct to an existing plan, often alongside microneedling, and who are comfortable proceeding on early, largely uncontrolled human evidence. If you would only be satisfied by a treatment with a mature randomized-trial base, exosomes are not that yet, and we will say so in the room.

Neither suits every cause of hair loss. Thyroid disease, iron deficiency, medication effects, telogen effluvium after illness or stress, and scarring alopecias all present as thinning hair, and none are managed by starting with a scalp procedure. That is much of what the consultation is for, and it reflects how we approach regenerative medicine: work out the driver first.

Can You Combine Them?

They are not mutually exclusive, and combination is a recognized pattern here. The PRP literature shows the principle: PRP plus minoxidil outperformed either alone across six randomized trials and 343 participants (Xiao et al., 2024, DOI).

What we will not claim is that any published trial establishes injected PRP plus topical exosomes beats PRP alone. We looked while writing this and found none we would be comfortable citing, so we are not making that claim. Sequencing is decided case by case.

How the Decision Actually Gets Made

In person, after your scalp is examined, your history taken and reversible contributors investigated. It turns on the pattern and duration of the thinning, whether there is an underlying driver, what you have already tried, and how you weigh a mature evidence base against an emerging one. Nothing here is a diagnosis or a recommendation for any individual.

Frequently Asked Questions

Are exosomes better than PRP for hair loss?

The published evidence does not support that claim. PRP has multiple randomized controlled trials and several meta-analyses in androgenetic alopecia (Zhang et al., 2023, DOI). Exosome hair research in humans amounts to a small number of studies in around 125 patients, mostly uncontrolled (Queen and Avram, 2024, DOI). Exosomes are investigational.

Do you inject exosomes into the scalp?

No. At Arbour Longevity exosomes are applied topically to the scalp surface only, typically after microneedling. They are never injected here.

Will exosomes regrow my hair?

We cannot tell you that, and we will not. Exosome preparations are investigational, are not a cure for hair loss, and are not proven to regrow hair. The available human studies are small and largely uncontrolled, and reviewers have called for larger well-designed trials before efficacy is considered established (Kost et al., 2022, DOI; Queen and Avram, 2024, DOI).

Does PRP actually work for pattern hair loss?

The randomized-trial evidence favors it for hair density. A meta-analysis of nine trials in 238 patients found PRP increased hair density at three and six months versus placebo, with no serious adverse reactions reported (Zhang et al., 2023, DOI). Reviewers pooling the wider literature note the studies are small and preparation methods vary (Kieling et al., 2024, DOI).

How long before I know whether it is working?

Think in months. Trials measured PRP outcomes at three and six months (Zhang et al., 2023, DOI) and to twelve months in the topical exosome study (Wan et al., 2025, DOI). The follicle cycle sets that pace.

Is PRP safe, given it is my own blood?

Being autologous—prepared from your own blood—is a genuine advantage. In the randomized-trial meta-analysis, adverse reactions were reported in two of seven studies and none were serious (Zhang et al., 2023, DOI). Individual suitability is still assessed in person.

What if my hair loss is not pattern hair loss?

Then the answer may be neither. Pattern hair loss involves progressive follicular miniaturization driven by genetic, hormonal, inflammatory and oxidative factors (Chen et al., 2025, DOI), and looks different from a nutritional, thyroid, medication-related or scarring cause. Identifying which you have comes before choosing a procedure.

Hair Restoration Consultations in Ann Arbor

We assess the scalp in person before recommending anything. Our hair restoration approach includes PRP, topical exosomes and microneedling, within our broader regenerative medicine program.

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner. We are at 2217 Packard St #15, Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside—no meters, no parking structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before visiting so we can help.

Call (734) 436-3357 or book your first visit. The first-visit consultation is $35, applied toward your treatment plan.

Clinical information on this page is drawn from articles retrieved from PubMed and is provided for education. It is not medical advice, not a diagnosis, and not a promise of any individual result. Exosome preparations described here are investigational and are used topically only.